125 related articles for article (PubMed ID: 18022825)
1. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
Wesierska-Gadek J; Kramer MP; Schmid G
J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
3. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
4. Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells.
Wesierska-Gadek J; Kramer M; Schmid G
J Cell Biochem; 2006 Dec; 99(6):1664-76. PubMed ID: 16823773
[TBL] [Abstract][Full Text] [Related]
5. Combining an FPTase inhibitor with cisplatin facilitates induction of apoptosis in human A549 lung cancer cells.
Weber F; Siska P; Kramer M; Zulehner N; Hackl S; Wesierska-Gádek J
J Exp Ther Oncol; 2011; 9(1):53-65. PubMed ID: 21275266
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Ageberg M; Rydström K; Lindén O; Linderoth J; Jerkeman M; Drott K
Exp Cell Res; 2011 May; 317(8):1179-91. PubMed ID: 21324313
[TBL] [Abstract][Full Text] [Related]
8. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.
Xie J; Wang BS; Yu DH; Lu Q; Ma J; Qi H; Fang C; Chen HZ
Int J Oncol; 2011 Feb; 38(2):409-17. PubMed ID: 21132264
[TBL] [Abstract][Full Text] [Related]
9. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
Cohen-Jonathan E; Toulas C; Ader I; Monteil S; Allal C; Bonnet J; Hamilton AD; Sebti SM; Daly-Schveitzer N; Favre G
Radiat Res; 1999 Oct; 152(4):404-11. PubMed ID: 10477917
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
Girgert R; Hohnecker A; Wittrock J; Schweizer P
Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Medicago scutellata trypsin inhibitor (MsTI) on cisplatin-induced cytotoxicity in human breast and cervical cancer cells.
Lanza A; Tava A; Catalano M; Ragona L; Singuaroli I; Robustelli della Cuna FS; Robustelli della Cuna G
Anticancer Res; 2004; 24(1):227-33. PubMed ID: 15015601
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
[TBL] [Abstract][Full Text] [Related]
13. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.
Fokstuen T; Rabo YB; Zhou JN; Karlson J; Platz A; Shoshan MC; Hansson J; Linder S
Anticancer Res; 1997; 17(4A):2347-52. PubMed ID: 9252645
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
[TBL] [Abstract][Full Text] [Related]
16. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Tsui SK; Ng PK; Leung PY; Kumta SM
J Orthop Res; 2011 Mar; 29(3):403-13. PubMed ID: 20886653
[TBL] [Abstract][Full Text] [Related]
17. Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU.
Kavgaci H; Ozdemir F; Ovali E; Yavuz A; Yavuz M; Aydin F
Chemotherapy; 2005 Oct; 51(6):319-23. PubMed ID: 16224182
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
Kim J; Seong J; Kim SH
Ann N Y Acad Sci; 2004 Dec; 1030():95-102. PubMed ID: 15659785
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.
Sepp-Lorenzino L; Tjaden G; Moasser MM; Timaul N; Ma Z; Kohl NE; Gibbs JB; Oliff A; Rosen N; Scher HI
Prostate Cancer Prostatic Dis; 2001; 4(1):33-43. PubMed ID: 12497061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
